Perrigo naproxen approval
This article was originally published in The Tan Sheet
Executive Summary
Private labeler receives FDA approval to manufacture and market Rx naproxen tablets in 250 mg, 375 mg and 500 mg doses, Perrigo announces April 28. The product, equivalent to Roche's Naprosyn, is "indicated for the treatment of arthritis, tendonitis, bursitis and for the relief of mild to moderate pain," according to Perrigo. The firm completed its acquisition of generic drug manufacturer Agis last month (1"The Tan Sheet" March 21, 2005, In Brief)...